{"id":9683,"date":"2011-02-28T00:00:00","date_gmt":"2011-02-27T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2011\/02\/28\/descobreixen-una-substancia-que-actua-contra-el-genoma-fosc-del-cancer\/"},"modified":"2020-05-13T19:50:52","modified_gmt":"2020-05-13T17:50:52","slug":"descobreixen-una-substancia-que-actua-contra-el-genoma-fosc-del-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2011\/02\/descobreixen-una-substancia-que-actua-contra-el-genoma-fosc-del-cancer\/","title":{"rendered":"Descobreixen una subst\u00e0ncia que actua contra el \u2018genoma fosc\u2019 del c\u00e0ncer"},"content":{"rendered":"

Un estudi coordinat per l\u2019investigador Manel Esteller, investigador ICREA de ‘IDIBELL, ha identificat una subst\u00e0ncia que inhibeix el creixement del c\u00e0ncer mitjan\u00e7ant l\u2019activaci\u00f3 de<\/p>\n

l\u2019anomenat \u201cgenoma fosc\u201d (o ADN no-codificant) i de les mol\u00e8cules de micro-ARN. L\u2019estudi es publica aquesta setmana en la prestigiosa revista cient\u00edfica<\/p>\n

<\/span>Proceedings of the National Academy of Sciences (PNAS)<\/span><\/a>.<\/span> <\/p>\n

Les c\u00e8l\u00b7lules del cos hum\u00e0 posseeixen un genoma (el conjunt del nostre ADN) que codifica les nostres prote\u00efnes, com la queratina de la pell o l\u2019hemoglobina de la sang. Aquest genoma amb ADN codificant nom\u00e9s representa el 5% del nostre material gen\u00e8tic. El 95% restant es coneix com a genoma fosc o ADN no-codificant i la seva funci\u00f3 \u00e9s en bona part desconeguda. Una part d\u2019aquest ADN produeix unes petites mol\u00e8cules anomenades microARN encarregades d\u2019activar o desactivar els gens. En els darrers anys s\u2019ha demostrat que les alteracions en aquestes mol\u00e8cules estan relacionades amb la formaci\u00f3 de tumors. <\/p>\n

Enoxacina<\/strong> <\/p>\n

<\/strong> Els investigadors han demostrat que la petita mol\u00e8cula enoxacina, utilitzada en compostos antibacterians, s\u2019uneix a la prote\u00efna que construeix els micro-ARN i estimula la seva activitat inhibidora del creixement del tumor. Segons l\u2019investigador Manel Esteller \u201c\u00e9s com si a un cotxe de segona m\u00e0 li posem un motor acabat de sortir de la f\u00e0brica\u201d. Ho han comprovat tant en c\u00e8l\u00b7lules de laboratori com en models experimentals animals i ara s\u2019haur\u00e0 d\u2019estudiar el seu funcionament en humans. Aix\u00ed ho ha dit Esteller, que ha destacat que l\u2019avantatge d\u2019aquest compost \u00e9s que es coneix el seu metabolisme i la seva seguretat en humans. <\/p>\n

Esteller ha afegit que \u201ctot i que pugui no arribar a aprovar-se l\u2019\u00fas d\u2019aquesta mol\u00e8cula en tractaments oncol\u00f2gics, la troballa obre la porta al disseny de nous f\u00e0rmacs que tinguin com a diana terap\u00e8utica els microARN. Mostrem a la ind\u00fastria farmac\u00e8utica una nova direcci\u00f3 cap a on dirigir els seus esfor\u00e7os en la ter\u00e0pia antitumoral\u201d. <\/p>\n

<\/strong> Refer\u00e8ncia de l\u2019article<\/strong> <\/p>\n

<\/strong> Sonia Melo*, Alberto Villanueva*, Catia Moutinho*, Ver\u00f3nica Davalos*, Ricardo Spizzo, Cristina Ivan , Simona Rossi, Fernando Setien*, Oriol Casanovas*, Laia Sio-Riudalbas*, Javier Carmona*, Jordi Carrere*, August Vidal*, \u00c1lvaro Aytes*, Sara Puertas*, Santiagio Ropero, Raghu Kalluri, Carlo M. Croce, George A. Calin, Manel Esteller*. The small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TRBP-mediated microRNA processing. Proceedings of the National Academy of Science USA (PNAS)<\/em>, Early Edition, February 28th<\/sup> 2011.<\/p>\n","protected":false},"excerpt":{"rendered":"

La troballa obre la porta a nous f\u00e0rmacs que podrien revolucionar el tractament oncol\u00f2gic Enoxacina Refer\u00e8ncia de l\u2019article<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-11 00:43:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9683"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9683"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9683\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}